Ti-22Nb-6Zr(at%)合金的超弹性和形状记忆效应

用弯曲法和拉伸法测定Ti-22Nb-6Zr（at％）合金的超弹性和形状记忆效应，研究固溶处理温度对Ti-22Nb-6Zr合金组织结构及性能的影响。结果表明：固溶处理后Ti-22Nb-6Zr合金的室温组织为单一的β相，晶粒尺寸随固溶处理温度升高而增大；合金的静态弹性模量小于30GPa；Ti-22Nb-6Zr合金具有良好的超弹性和一定的形状记忆效应。室温下变形，合金的超弹性和形状记忆效应随固溶处理温度升高而提高。900℃固溶处理后的合金在室温下拉伸变形，应变为5％时，总的最大回复应变达4．12％，其中超弹性回复应变为3．91％，记忆回复应变为0.21％。     

EFFECT OF AGING ON HYDROGEN EMBRITTLEMENT SUSCEPTIBILITY OF STEEL Cr21Ni6Mn9N

Effects of 650℃ aging for 1—1000 h on structure and hydrogen embrittlement susceptibility(HES)of steel Cr21Ni6Mn9N have been investigated.The results show that M_(23)C_6 typecarbide precipitates at grain boundaries and Cr-depletive region appears beside them duringaging.The precipitates grow and connect each other as the aging time prolongs.Meanwhile,the degree of Cr-depletion aggravates first and then recovers gradually while the aging time isvery long,i.e.,1000 h.The HES of the steel increases with increasing aging time but does notreduce with the recovery of Cr content at the Cr-depletive region.That implies that the ex-isting of carbides at grain boundaries might be the main reason which promotes the HES ofsteel during aging.     

化学气相沉积法制备碳化铬薄膜的研究

以三（2,2,6,6-四甲基-3,5-庚二酮）化铬为前驱体,采用化学气相沉积（CVD）法在氧化铝（Al₂O₃）陶瓷基板上制备碳化铬（Cr₃C₂）薄膜,其中沉积温度为723 K至923 K,沉积时间为1 200 s。研究了不同沉积温度对Cr₃C₂薄膜的相组成、择优取向、宏观表面、微观结构及电学性能的影响。结果表明,在723 K至923 K下制备得到具有高度（130）择优取向的Cr₃C₂薄膜。随着沉积温度的升高,Cr₃C₂薄膜表面先由光滑变粗糙,后逐渐变光滑;薄膜晶粒呈椭球型生长;薄膜的厚度先增加后减小,从而导致电阻先减小后增大。在798 K时制备得到厚度最大且电阻最小的（130）择优取向的最佳Cr₃C₂薄膜。同时,在实验条件下Cr₃C₂薄膜表面存在少量的碳和Cr₂O₃。     

30%苄氨基嘌呤悬浮剂对芹菜生长和品质的影响

田间条件下研究了不同浓度苄氨基嘌呤悬浮剂对芹菜生长和品质的影响。结果表明,剂量浓度在60~120 mg/kg范围内均可提高芹菜的株高和产量,120 mg/kg剂量浓度处理对亩产量和株高的提高幅度达到了显著水平(P<0.05);药剂对芹菜安全性和品质分析结果表明,试验药剂30%苄氨基嘌呤悬浮剂各剂量浓度对芹菜均没有明显药害,对芹菜的干物质重量、维生素(Vc)和可溶性固形物含量均无显著影响。     

Effects of Adenine Methylation on the Structure and Thermodynamic Stability of a DNA Minidumbbell

DNA methylation is a prevalent regulatory modification in prokaryotes and eukaryotes. N¹-methyladenine (m¹A) and N⁶-methyladenine (m⁶A) have been found to be capable of altering DNA structures via disturbing Watson–Crick base pairing. However, little has been known about their influences on non-B DNA structures, which are associated with genetic instabilities. In this work, we investigated the effects of m¹A and m⁶A on both the structure and thermodynamic stability of a newly reported DNA minidumbbell formed by two TTTA tetranucleotide repeats. As revealed by the results of nuclear magnetic resonance spectroscopic studies, both m¹A and m⁶A favored the formation of a T·m¹A and T·m⁶A Hoogsteen base pair, respectively. More intriguingly, the m¹A and m⁶A modifications brought about stabilization and destabilization effects on the DNA minidumbbell, respectively. This work provides new biophysical insights into the effects of adenine methylation on the structure and thermodynamic stability of DNA.     

ATP-Independent Initiation during Cap-Independent Translation of m6A-Modified mRNA

The methylation of adenosine in the N⁶ position (m⁶A) is a widely used modification of eukaryotic mRNAs. Its importance for the regulation of mRNA translation was put forward recently, essentially due to the ability of methylated mRNA to be translated in conditions of inhibited cap-dependent translation initiation, e.g., under stress. However, the peculiarities of translation initiation on m⁶A-modified mRNAs are not fully known. In this study, we used toeprinting and translation in a cell-free system to confirm that m⁶A-modified mRNAs can be translated in conditions of suppressed cap-dependent translation. We show for the first time that m⁶A-modified mRNAs display not only decreased elongation, but also a lower efficiency of translation initiation. Additionally, we report relative resistance of m⁶A-mRNA translation initiation in the absence of ATP and inhibited eIF4A activity. Our novel findings indicate that the scanning of m⁶A-modified leader sequences is performed by a noncanonical mechanism.     

Interleukin 6 and Aneurysmal Subarachnoid Hemorrhage. A Narrative Review

Interleukin 6 (IL-6) is a prominent proinflammatory cytokine. Neuroinflammation in general, and IL-6 signaling in particular, appear to play a major role in the pathobiology and pathophysiology of aneurysm formation and aneurysmal subarachnoid hemorrhage (SAH). Most importantly, elevated IL-6 CSF (rather than serum) levels appear to correlate with delayed cerebral ischemia (DCI, “vasospasm”) and secondary (“vasospastic”) infarctions. IL-6 CSF levels may also reflect other forms of injury to the brain following SAH, i.e., early brain damage and septic complications of SAH and aneurysm treatment. This would explain why many researchers have found an association between IL-6 levels and patient outcomes. These findings clearly suggest CSF IL-6 as a candidate biomarker in SAH patients. However, at this point, discrepant findings in variable study settings, as well as timing and other issues, e.g., defining proper clinical endpoints (i.e., secondary clinical deterioration vs. angiographic vasospasm vs. secondary vasospastic infarct) do not allow for its routine use. It is also tempting to speculate about potential therapeutic measures targeting elevated IL-6 CSF levels and neuroinflammation in SAH patients. Corticosteroids and anti-platelet drugs are indeed used in many SAH cases (not necessarily with the intention to interfere with detrimental inflammatory signaling), however, no convincing benefit has been demonstrated yet. The lack of a robust clinical perspective against the background of a relatively large body of data linking IL-6 and neuroinflammation with the pathophysiology of SAH is somewhat disappointing. One underlying reason might be that most relevant studies only report correlative data. The specific molecular pathways behind elevated IL-6 levels in SAH patients and their various interactions still remain to be delineated. We are optimistic that future research in this field will result in a better understanding of the role of neuroinflammation in the pathophysiology of SAH, which in turn, will translate into the identification of suitable biomarkers and even potential therapeutic targets.     

Potential Antitumor Effects of 6-Gingerol in p53-Dependent Mitochondrial Apoptosis and Inhibition of Tumor Sphere Formation in Breast Cancer Cells

Hormone-specific anticancer drugs for breast cancer treatment can cause serious side effects. Thus, treatment with natural compounds has been considered a better approach as this minimizes side effects and has multiple targets. 6-Gingerol is an active polyphenol in ginger with various modalities, including anticancer activity, although its mechanism of action remains unknown. Increases in the level of reactive oxygen species (ROS) can lead to DNA damage and the induction of DNA damage response (DDR) mechanism, leading to cell cycle arrest apoptosis and tumorsphere suppression. Epidermal growth factor receptor (EGFR) promotes tumor growth by stimulating signaling of downstream targets that in turn activates tumor protein 53 (p53) to promote apoptosis. Here we assessed the effect of 6-gingerol treatment on MDA-MB-231 and MCF-7 breast cancer cell lines. 6-Gingerol induced cellular and mitochondrial ROS that elevated DDR through ataxia-telangiectasia mutated and p53 activation. 6-Gingerol also induced G0/G1 cell cycle arrest and mitochondrial apoptosis by mediating the BAX/BCL-2 ratio and release of cytochrome c. It also exhibited a suppression ability of tumorsphere formation in breast cancer cells. EGFR/Src/STAT3 signaling was also determined to be responsible for p53 activation and that 6-gingerol induced p53-dependent intrinsic apoptosis in breast cancer cells. Therefore, 6-gingerol may be used as a candidate drug against hormone-dependent breast cancer cells.     

Design,Synthesis, and Biological Evaluation of Novel 6H-Benzo[c]chromen-6-one Derivatives as Potential Phosphodiesterase II Inhibitors

Urolithins (hydroxylated 6H-benzo[c]chromen-6-ones) are the main bioavailable metabolites of ellagic acid (EA), which was shown to be a cognitive enhancer in the treatment of neurodegenerative diseases. As part of this research, a series of alkoxylated 6H-benzo[c]chromen-6-one derivatives were designed and synthesized. Furthermore, their biological activities were evaluated as potential PDE2 inhibitors, and the alkoxylated 6H-benzo[c]chromen-6-one derivative 1f was found to have the optimal inhibitory potential (IC₅₀: 3.67 ± 0.47 μM). It also exhibited comparable activity in comparison to that of BAY 60-7550 in vitro cell level studies.